Roche’s ophthalmology drug Vabysmo (faricimab) has become the first product to be approved by the UK medicines regulator under the Access Consortium, an international work-sharing scheme that the agency joined post-Brexit to accelerate drug approvals.
The Medicines and Healthcare products Regulatory Agency joined the consortium in October 2020 to work with regulators from Australia, Canada, Singapore and Switzerland to promote greater regulatory collaboration and alignment of regulatory requirements
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?